Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 4.2%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s share price fell 4.2% on Tuesday . The stock traded as low as $22.65 and last traded at $22.67. 54,551 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 516,126 shares. The stock had previously closed at $23.66.

Analysts Set New Price Targets

Several brokerages recently weighed in on ARCT. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday. Canaccord Genuity Group reduced their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Finally, William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $64.86.

Arcturus Therapeutics Price Performance

The firm’s fifty day moving average price is $30.12 and its two-hundred day moving average price is $32.62. The stock has a market cap of $570.92 million, a price-to-earnings ratio of -5.75 and a beta of 2.65.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.17. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The firm had revenue of $38.01 million for the quarter, compared to analyst estimates of $22.12 million. On average, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -4.39 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Pad Chivukula sold 26,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $40.01, for a total value of $1,040,260.00. Following the sale, the chief operating officer now owns 447,448 shares in the company, valued at approximately $17,902,394.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 13.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC grew its position in Arcturus Therapeutics by 224.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 114,810 shares of the biotechnology company’s stock worth $3,620,000 after purchasing an additional 79,387 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Arcturus Therapeutics during the 4th quarter valued at approximately $927,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at approximately $2,738,000. AQR Capital Management LLC grew its position in shares of Arcturus Therapeutics by 239.8% during the 3rd quarter. AQR Capital Management LLC now owns 172,202 shares of the biotechnology company’s stock valued at $4,400,000 after acquiring an additional 121,526 shares during the period. Finally, Hennion & Walsh Asset Management Inc. grew its position in shares of Arcturus Therapeutics by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after acquiring an additional 778 shares during the period. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.